Estelle Colin et al.
OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results and identified 13% additional candidate variants
Frontiers in Cell and Developmental Biology 2022, vol. 10
doi: 10.3389/fcell.2022.1021785